Business
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI® (maralixibat) oral solution of $10.9 million. -
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI® (maralixibat) oral solution of $10.9 million.\n\n- Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.\n\n“The first quarter was tremendously successful for Mirum. Rapid growth in LIVMARLI revenue means that children suffering from pruritus associated with Alagille syndrome finally have a treatment option and are getting the care they need,” said Chris Peetz, president and chief executive officer. “I am thrilled with what the Mirum team has accomplished and look forward to helping many more patients as we pursue potential regulatory approvals in international markets. We see continued progress ahead for Mirum as we advance our LIVMARLI and volixibat development programs.”\n\nRecent Publications\n\n\nHepatology Communications recently published data from the maralixibat Phase 2 INDIGO study evaluating patients with PFIC.\n\n\nThe European Medical Journal published an article summarizing predictors of six-year event-free survival in patients with Alagille syndrome treated with maralixibat.\n\n\nUpcoming Anticipated Milestones\n\n\nLIVMARLI (maralixibat)\n\n\nTopline data evaluating more than 90 patients in the MARCH-PFIC Phase 3 clinical trial expected in the fourth quarter of 2022.\n\n\nLIVMARLI approval by the European Medicines Agency for cholestatic liver disease in patients with Alagille syndrome, expected in the fourth quarter of 2022.\n\n\nEMBARK Phase 2b clinical trial for biliary atresia currently enrolling; topline data anticipated in 2023.\n\n\n\n\nVolixibat\n\n\nInterim analysis expected for VISTAS Phase 2b clinical trial for primary sclerosing cholangitis in the fourth quarter of 2022.\n\n\nInterim analysis expected for OHANA Phase 2b clinical trial for intrahepatic cholestasis of pregnancy in the fourth quarter of 2022.\n\n\nEnrollment ongoing for VANTAGE Phase 2b clinical trial for primary biliary cholangitis; interim analysis expected in 2023.\n\n\n\n\n\nFinancial Results\n\n\nNet product revenue of LIVMARLI for the quarter ended March 31, 2022 was $10.9 million, compared to none fo...